| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Carlos Cáceres | Q39854931 |
| Jessica E Haberer | Q57891949 | ||
| K Rivet Amico | Q58238816 | ||
| David R Bangsberg | Q60227555 | ||
| Jared M Baeten | Q89443633 | ||
| Nelly Mugo | Q90832458 | ||
| P2093 | author name string | Peter Anderson | |
| Francois Venter | |||
| Kevin O'Reilly | |||
| Pedro Goicochea | |||
| Kathryn Curran | |||
| Florence Koechlin | |||
| P2860 | cites work | Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen | Q40304165 |
| Women's patterns of contraceptive use. | Q41625418 | ||
| Optimal recall period and response task for self-reported HIV medication adherence | Q43753135 | ||
| Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters | Q44517872 | ||
| HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. | Q45187803 | ||
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study | Q46333832 | ||
| Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression | Q46474715 | ||
| Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention | Q46627552 | ||
| Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up | Q57259766 | ||
| Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers | Q21558500 | ||
| Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis | Q22242951 | ||
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| A pill for HIV prevention: déjà vu all over again? | Q26824606 | ||
| Preexposure prophylaxis for HIV prevention: where have we been and where are we going? | Q26825042 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial | Q28292876 | ||
| Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy | Q28472810 | ||
| The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies | Q28487926 | ||
| Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa | Q28533158 | ||
| Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial | Q28533828 | ||
| Preexposure prophylaxis for HIV infection among African women | Q29620077 | ||
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
| The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy | Q33507274 | ||
| Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence | Q33765789 | ||
| Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection | Q33948938 | ||
| HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial | Q34046430 | ||
| A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa | Q34180749 | ||
| Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level | Q34283336 | ||
| Real-time adherence monitoring for HIV antiretroviral therapy | Q34284065 | ||
| Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence | Q35121855 | ||
| A proposal for quality standards for measuring medication adherence in research | Q36210156 | ||
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission | Q36353342 | ||
| Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? | Q36951006 | ||
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Q37042094 | ||
| Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation | Q37172505 | ||
| Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue | Q37258298 | ||
| Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda | Q37404785 | ||
| Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe | Q37463319 | ||
| Antiretroviral therapy and management of HIV infection | Q37770721 | ||
| Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prevention of HIV/AIDS | Q7242372 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 1277-1285 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm | |
| P478 | volume | 29 |
| Q90351366 | 'I'm waiting for that': Interest in the use of PrEP for safer conception in Botswana |
| Q92437893 | A Mobile Application to Collect Daily Data on Preexposure Prophylaxis Adherence and Sexual Behavior Among Men Who Have Sex With Men: Use Over Time and Comparability With Conventional Data Collection |
| Q41570992 | Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men |
| Q38849535 | Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence |
| Q42334798 | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines |
| Q59355921 | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018 |
| Q52571189 | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. |
| Q46479831 | Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa |
| Q59326978 | Clinical exigencies, psychosocial realities: negotiating HIV pre-exposure prophylaxis beyond the cascade among gay, bisexual and other men who have sex with men in Canada |
| Q92671810 | Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up |
| Q92105285 | Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure |
| Q36710299 | Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice |
| Q41990298 | Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial |
| Q37677215 | Defining the HIV pre-exposure prophylaxis care continuum |
| Q40116624 | Delivering PrEP to pregnant and breastfeeding women in sub-Saharan africa: The implementation science frontier |
| Q58594052 | Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies |
| Q59813153 | Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study |
| Q92918284 | Global implementation of PrEP for HIV prevention: setting expectations for impact |
| Q55299659 | Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. |
| Q47398084 | Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection |
| Q99622758 | Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies |
| Q37341579 | Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study |
| Q38651723 | Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants |
| Q45999968 | Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. |
| Q39127005 | Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis |
| Q91957399 | Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States |
| Q89819868 | Modeling HIV Pre-Exposure Prophylaxis |
| Q89950649 | Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries |
| Q90709655 | Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis |
| Q89514586 | Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings |
| Q52323543 | Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling. |
| Q64245540 | Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care |
| Q56911319 | Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships |
| Q92727139 | Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study |
| Q90693843 | PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples |
| Q42696079 | PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships |
| Q37352576 | PrEP implementation research in Africa: what is new? |
| Q94671913 | PrEP rollout in Africa: status and opportunity |
| Q99716499 | Pre-Exposure Prophylaxis Integration Into Family Planning Services at Title X Clinics in the Southeastern United States: Protocol for a Mixed Methods Hybrid Type I Effectiveness Implementation Study (Phase 2 ATN 155) |
| Q55715002 | Pre-exposure Prophylaxis: The Delivery Challenge. |
| Q58077943 | Preexposure Prophylaxis Monitoring in New York City: A Public Health Approach |
| Q42390812 | Preexposure Prophylaxis and Patient Centeredness: A Call for Holistically Protecting and Promoting the Health of Gay Men. |
| Q33656112 | Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation |
| Q36202628 | Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PREP) among Female Sex Workers in South India |
| Q92213693 | Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa |
| Q40603253 | Psycho-social Correlates of Condom Use and HIV Testing among MSM Refugees in Beirut, Lebanon |
| Q40186272 | Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study |
| Q58587972 | Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| Q64110144 | Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART? |
| Q36994992 | Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study |
| Q46103694 | Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. |
| Q58591701 | Short Message Service (SMS) Surveys Assessing Pre-exposure Prophylaxis (PrEP) Adherence and Sexual Behavior are Highly Acceptable Among HIV-Uninfected Members of Serodiscordant Couples in East Africa: A Mixed Methods Study |
| Q57159105 | Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial |
| Q90577276 | Syndemics and the PrEP Cascade: Results from a Sample of Young Latino Men Who Have Sex with Men |
| Q60915851 | Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions |
| Q92641307 | Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa |
| Q36443803 | Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women |
| Q37018274 | The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study |
| Q64098099 | The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis |
| Q36988613 | The preexposure prophylaxis revolution; from clinical trials to programmatic implementation |
| Q58571565 | Understanding and measuring uptake and coverage of oral pre-exposure prophylaxis delivery among adolescent girls and young women in sub-Saharan Africa |
| Q89840867 | Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study |
| Q40227281 | Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. |
| Q90368278 | Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men |
| Q38633784 | What people want from sex and preexposure prophylaxis. |
| Q40708259 | When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling |
| Q35993762 | Who Will Use Pre-Exposure Prophylaxis (PrEP) and Why?: Understanding PrEP Awareness and Acceptability amongst Men Who Have Sex with Men in the UK--A Mixed Methods Study |
| Q48101425 | Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men. |
| Q53429666 | Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa. |
| Q99638128 | Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial |
Search more.